References

Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma

10.1056/nejmoa1915745 · 2020 · External reference

Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer

10.1056/nejmoa2202170 · 2022 · External reference

Intratumoral Tcf1+PD-1+CD8+ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy

10.1016/j.immuni.2018.12.021 · 2019 · External reference

Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade

10.1038/s41590-019-0312-6 · 2019 · External reference

Clonal replacement of tumor-specific T cells following PD-1 blockade

10.1038/s41591-019-0522-3 · 2019 · External reference

Antitumor immune responses in B2M-deficient cancers

10.1158/2326-6066.cir-23-0139 · 2023 · External reference

An intra-tumoral niche maintains and differentiates stem-like CD8 T cells

10.1038/s41586-019-1836-5 · 2019 · External reference

Tertiary lymphoid structures improve immunotherapy and survival in melanoma

10.1038/s41586-019-1914-8 · 2020 · External reference

A reservoir of stem-like CD8+ T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response

10.1126/sciimmunol.abg7836 · 2021 · External reference

CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor

10.1016/j.immuni.2022.12.002 · 2023 · External reference

Oncology meets immunology: the cancer-immunity cycle

10.1016/j.immuni.2013.07.012 · 2013 · External reference

Elements of cancer immunity and the cancer-immune set point

10.1038/nature21349 · 2017 · External reference

Cancer immunology. The "cancer immunogram"

10.1126/science.aaf2834 · 2016 · External reference

Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity

10.1126/science.1164206 · 2008 · External reference

Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells

10.1158/2159-8290.cd-15-0510 · 2016 · External reference

Critical role for CD103(+)/CD141(+) dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma

10.1016/j.ccell.2016.06.003 · 2016 · External reference

Mutations associated with acquired resistance to PD-1 blockade in melanoma

10.1056/nejmoa1604958 · 2016 · External reference

Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent

10.1126/science.aaf0683 · 2017 · External reference

Type I interferon is selectively required by dendritic cells for immune rejection of tumors

10.1084/jem.20101158 · 2011 · External reference

Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12

10.1016/j.immuni.2018.09.024 · 2018 · External reference

Peripheral T cell expansion predicts tumour infiltration and clinical response

10.1038/s41586-020-2056-8 · 2020 · External reference

In vivo labeling reveals continuous trafficking of TCF-1+ T cells between tumor and lymphoid tissue

10.1084/jem.20210749 · 2022 · External reference

Chemotherapy but not the tumor draining lymph nodes determine the immunotherapy response in secondary tumors

10.1016/j.isci.2020.101056 · 2020 · External reference

Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy

10.1172/jci.insight.124507 · 2018 · External reference

Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes

10.1016/j.cell.2023.02.021 · 2023 · External reference

STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors

10.1016/j.immuni.2014.10.019 · 2014 · External reference

Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy

10.1158/1078-0432.ccr-17-3427 · 2018 · External reference

Systemic immunity is required for effective cancer immunotherapy

10.1016/j.cell.2016.12.022 · 2017 · External reference

Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors

10.1172/jci45817 · 2012 · External reference

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

10.1038/nature25501 · 2018 · External reference

Metabolic competition in the tumor microenvironment is a driver of cancer progression

10.1016/j.cell.2015.08.016 · 2015 · External reference

Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells

10.1038/nature20554 · 2016 · External reference

PD-1 blockade induces responses by inhibiting adaptive immune resistance

10.1038/nature13954 · 2014 · External reference

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

10.1016/s1470-2045(19)30274-8 · 2019 · External reference

The PD-1/PD-L1-checkpoint restrains T cell immunity in tumor-draining lymph nodes

10.1016/j.ccell.2020.09.001 · 2020 · External reference

Systemic dysfunction and plasticity of the immune macroenvironment in cancer models

10.1038/s41591-020-0892-6 · 2020 · External reference

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

10.1126/science.aan3706 · 2018 · External reference

Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma

10.1038/s41591-022-01695-5 · 2022 · External reference

Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1

10.1038/s41591-022-01698-2 · 2022 · External reference

Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients

10.1126/science.abf3363 · 2021 · External reference

Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial

10.1038/s41591-023-02453-x · 2023 · External reference

Safety and efficacy of fecal microbiota transplantation in solid cancers resistant to immune checkpoint inhibitors: results of the MITRIC trial

10.1136/jitc-2026-015122 · 2026 · External reference

Body composition and checkpoint inhibitor treatment outcomes in advanced melanoma: a multicenter cohort study

10.1093/jnci/djaf039 · 2025 · External reference

Correction of age-associated defects in dendritic cells enables CD4+ T cells to eradicate tumors

10.1016/j.cell.2024.05.026 · 2024 · External reference

T cell immune awakening in response to immunotherapy is age-dependent

10.1016/j.ejca.2021.11.015 · 2022 · External reference

Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer

10.1001/jamaoncol.2019.2785 · 2019 · External reference

Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer

10.1200/jco.2018.79.0006 · 2018 · External reference

Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications

10.1200/jco.19.00189 · 2019 · External reference

Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade

10.1016/j.cell.2016.11.022 · 2016 · External reference

Sustained type I interferon signaling as a mechanism of resistance to PD-1 blockade

10.1038/s41422-019-0224-x · 2019 · External reference

Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma

10.1016/j.ccr.2014.04.021 · 2014 · External reference

Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival

10.1016/j.ccr.2014.04.005 · 2014 · External reference

Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition

10.1016/j.immuni.2016.03.012 · 2016 · External reference

Tumour-retained activated CCR7+ dendritic cells are heterogeneous and regulate local anti-tumour cytolytic activity

10.1038/s41467-024-44787-1 · 2024 · External reference

Positioning and reversible suppression of CCR7+ dendritic cells in perivascular tumor niches shape cancer immunity

10.1016/j.immuni.2025.11.020 · 2026 · External reference

TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination

10.4049/jimmunol.0900974 · 2009 · External reference

Multi-scale characterization of tumor-draining lymph nodes in resectable lung cancer treated with neoadjuvant immune checkpoint inhibitors

10.1016/j.ebiom.2022.104265 · 2022 · External reference

STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors

10.1016/j.immuni.2014.10.017 · 2014 · External reference

In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells

10.1158/0008-5472.can-09-0835 · 2009 · External reference

DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity

10.1038/ncomms15618 · 2017 · External reference

Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: Results of the PEMBRO-RT phase 2 randomized clinical trial

10.1001/jamaoncol.2019.1478 · 2019 · External reference

Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma

10.1200/jco.20.00290 · 2021 · External reference

Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy

10.1126/scitranslmed.aay3575 · 2020 · External reference

Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy

10.1136/jitc-2020-000867 · 2020 · External reference

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

10.1038/nature22079 · 2017 · External reference

Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer

10.1038/s41467-020-16079-x · 2020 · External reference

Association of short-chain fatty acids in the gut microbiome with clinical response to treatment with nivolumab or pembrolizumab in patients with solid cancer tumors

10.1001/jamanetworkopen.2020.2895 · 2020 · External reference

Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade

10.1038/s41591-018-0221-5 · 2019 · External reference

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis

10.1016/s1470-2045(18)30078-0 · 2018 · External reference

Impact of sarcopenia and inflammation on patients with advanced non-small cell lung cancer (NCSCL) treated with immune checkpoint inhibitors (ICIs): a prospective study

10.3390/cancers13246355 · 2021 · External reference

A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients - the ELDERS study

10.1016/j.esmoop.2020.100042 · 2021 · External reference

The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide

10.1126/science.1240537 · 2013 · External reference

The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy

10.1126/scitranslmed.aan3464 · 2018 · External reference

Lactobacillus rhamnosus GG induces cGAS/STING- dependent type I interferon and improves response to immune checkpoint blockade

10.1136/gutjnl-2020-323426 · 2022 · External reference

Motixafortide and pembrolizumab combined to nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic cancer: the COMBAT/KEYNOTE-202 trial

10.1158/1078-0432.ccr-21-0929 · 2021 · External reference

Defactinib, pembrolizumab, and gemcitabine in patients with advanced treatment refractory pancreatic cancer: a phase I dose escalation and expansion study

10.1158/1078-0432.ccr-22-0308 · 2022 · External reference

Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study

10.1200/jco.19.02105 · 2020 · External reference

Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma

10.1056/nejmoa2211437 · 2023 · External reference

Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma

10.1056/nejmoa2402604 · 2024 · External reference

Perioperative pembrolizumab for early-stage non-small-cell lung cancer

10.1056/nejmoa2302983 · 2023 · External reference

Perioperative durvalumab for resectable non-small-cell lung cancer

10.1056/nejmoa2304875 · 2023 · External reference

Perioperative nivolumab in resectable lung cancer

10.1056/nejmoa2311926 · 2024 · External reference

Nivolumab plus chemotherapy in epidermal growth factor receptor-mutated metastatic non-small-cell lung cancer after disease progression on epidermal growth factor receptor tyrosine kinase inhibitors: final results of CheckMate 722

10.1200/jco.23.01017 · 2024 · External reference

Updated data from IMbrave050: adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma

10.1016/j.jhep.2026.01.006 · 2026 · External reference

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

10.1038/s41586-021-03362-0 · 2021 · External reference

Regorafenib, ipilimumab, and nivolumab for patients with microsatellite stable colorectal cancer and disease progression with prior chemotherapy: a phase 1 nonrandomized clinical trial

10.1001/jamaoncol.2022.7845 · 2023 · External reference

Pembrolizumab plus docetaxel versus docetaxel for previously treated metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-921 trial

10.1200/jco-24-01283 · 2025 · External reference

Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study

10.1016/j.eclinm.2023.101917 · 2023 · External reference

TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis

10.1038/nature25492 · 2018 · External reference

Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study

10.1200/jco.19.01638 · 2020 · External reference

Overall survival with neoadjuvant nivolumab plus chemotherapy in lung cancer

10.1056/nejmoa2502931 · 2025 · External reference

Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma

10.1200/jco.22.00343 · 2023 · External reference

Randomized, open-label, phase III study of tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with advanced refractory melanoma (ILLUMINATE-301)

10.1200/jco.24.00727 · 2025 · External reference

Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial

10.1038/s41591-023-02760-3 · 2024 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response

10.1126/science.aaz7015 · 2021 · External reference

Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy

10.1126/science.abc3421 · 2020 · External reference

Age-related divergence of circulating immune responses in patients with solid tumors treated with immune checkpoint inhibitors

10.1038/s41467-025-58512-z · 2025 · External reference

Corticosteroids for immune-related adverse events and checkpoint inhibitor efficacy: analysis of six clinical trials

10.1200/jco.24.00191 · 2024 · External reference

Unresolved reference

External reference

Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients

10.1126/science.abb5920 · 2021 · External reference